Biostax

Biostax Net Margin

The Net Profit Margin of Biostax (BTAX) as of Nov 1, 2026 is -7,202.82 %. In the previous year, Net Profit Margin was -557,754.29 % — a change of -98.71% (higher).

Net Margin

-7,202.82 %

YoY

-98.71%

Last updated:

Net Profit Margin of Biostax is 2018 -7,202.82 % . Net Profit Margin of Biostax was 2017 -557,754.29 % . It decreases by -98.71% higher compared to the previous year.

Biostax's net margin stands at -7,202.8%, up from -87,916.7% several years earlier.

The Biostax Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2015
-87,916.67 USD
Jan 1, 2016
-557,754.29 USD
Jan 1, 2018
-7,202.82 USD
The Biostax Net Margin history
YEARNet MarginYoY
-7,202.82 %-98.71%
-557,754.29 %+534.41%
-87,916.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostax Stock analysis

What does Biostax do? Immune Therapeutics, Inc. develops and markets pharmaceutical, biotechnology, and MedTech products through its subsidiary BiostaxRx, which focuses on treating inflammaging disease. The company's product portfolio includes Londonal, a once-a-day immune system regulator for HIV/AIDS management, and JKB-122, a therapy targeting Autoimmune Hepatitis, NAFLD, and NASH with anti-fibrotic and anti-inflammatory properties. Biostax has partnerships in autoimmunity and immune restoration fields to deliver solutions for patients with autoimmunity, chronic inflammation, infection, and cancer. BiostaxRx specifically addresses inflammaging disease within its treatment focus. Biostax Corp's revenue streams come from the sale of Londonal and JKB-122 to healthcare providers and patients seeking treatments for immune-related conditions. The company markets its products to medical professionals and institutions specializing in autoimmune disorders, chronic inflammation, and oncology. Its focus on specific therapeutic areas allows it to target healthcare segments requiring immune modulation and anti-inflammatory solutions. The company's partnerships support its delivery of specialized treatments for chronic conditions such as HIV/AIDS, liver diseases, and cancer-related inflammation. The company's product lines are designed for specific patient segments including those with HIV/AIDS, Autoimmune Hepatitis, NAFLD, NASH, and inflammaging. Londonal is positioned for HIV/AIDS management while JKB-122 targets liver conditions and inflammation. BiostaxRx's focus on inflammaging disease aligns with the growing market for age-related immune health solutions. The company's marketing strategy emphasizes specialized treatments for complex conditions where current therapies are limited or ineffective. Biostax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostax stock

Net Profit Margin of Biostax is -7,202.82 % in 2018.

Net Profit Margin of Biostax changed from -557,754.29 % to -7,202.82 %, representing a -98.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Biostax since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Biostax with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biostax

All Key Metrics — Biostax